Alprostadil (Caverject/MUSE) Cost in South Dakota 2026

What Does Alprostadil Actually Cost in South Dakota in 2026?

The retail cash price for brand alprostadil in South Dakota sits at approximately $600 per month in 2026, which aligns with the national manufacturer list price set by Pfizer for Caverject and by Meda Pharmaceuticals for MUSE. That figure assumes a standard supply of doses used on demand. Because alprostadil is not taken daily, the per-dose cost can range from roughly $20 to $75 depending on the formulation, dose strength, and pharmacy, but most patients who rely on brand product without insurance pay close to the $600 monthly benchmark when accounting for typical use patterns.

Generic alprostadil injection products have entered the U.S. market and may be available at some South Dakota pharmacies for modestly less than the Pfizer brand, though pricing varies significantly by location within the state. Sioux Falls and Rapid City pharmacies generally carry the widest selection; rural South Dakota pharmacies may stock limited quantities or require special orders.

Alprostadil works by binding to EP2 and EP3 prostanoid receptors in cavernosal smooth muscle, triggering adenylyl cyclase activity and reducing intracellular calcium, which produces penile smooth-muscle relaxation and erection. The landmark Linet et al. trial published in the New England Journal of Medicine (N=296) confirmed that intracavernosal alprostadil produced erections sufficient for intercourse in 94% of injection attempts versus 0% with placebo, establishing alprostadil as a first-line second-step therapy after oral PDE5 inhibitors fail. The FDA originally approved Caverject in 1995 and maintains the current prescribing information on its Drugs@FDA database.

Pricing transparency remains limited in South Dakota because the state has no dedicated drug price transparency law for outpatient medications. Patients are strongly encouraged to call pharmacies directly and request the cash price before presenting a prescription.

Does South Dakota Medicaid Cover Alprostadil?

South Dakota Medicaid does not cover alprostadil for erectile dysfunction. This is a firm coverage exclusion rather than a prior-authorization hurdle. Erectile dysfunction medications are specifically excluded from South Dakota Medicaid's Preferred Drug List (PDL) formulary, consistent with federal Medicaid statute at 42 U.S.C. § 1396r-8(d)(2), which permits states to exclude drugs used for sexual dysfunction.

Patients enrolled in South Dakota Medicaid who require alprostadil must pay out of pocket unless they qualify for a limited exception. One narrow exception applies when alprostadil is prescribed for a non-ED indication, for example, the drug carries FDA approval for newborn ductus arteriosus maintenance, and adult off-label cardiovascular uses may receive different coverage treatment. For ED specifically, no Medicaid exception currently exists in South Dakota.

The South Dakota Department of Social Services publishes its PDL at dss.sd.gov, and providers can confirm the current exclusion status there. A 2021 JAMA Internal Medicine analysis found that 31 state Medicaid programs explicitly excluded all erectile dysfunction medications, and South Dakota is among them.

Dual-eligible patients (Medicare + Medicaid) should check their Part D plan separately, because Medicare Part D plans are not bound by the same ED exclusion policy and some plans do cover alprostadil with prior authorization.

Which Private Insurance Plans Cover Alprostadil in South Dakota?

Coverage varies widely. Many commercial plans in South Dakota treat erectile dysfunction medications as an optional benefit they can exclude, but a meaningful number of employer-sponsored plans do cover alprostadil with prior authorization.

Typical prior-authorization requirements across South Dakota commercial plans in 2026 include documentation of an organic etiology for ED (such as diabetes, post-radical prostatectomy status, or spinal cord injury), a trial of at least one oral PDE5 inhibitor (sildenafil or tadalafil), and a prescription from a urologist or endocrinologist rather than a primary care provider alone. The American Urological Association's 2018 ED guideline, updated 2024, states that "intracavernosal injection therapy with alprostadil, papaverine, or phentolamine is a well-established second-line therapy" for men who do not respond to or cannot tolerate PDE5 inhibitors, and insurers often cite this hierarchy when requiring documented PDE5 failure.

Marketplace (ACA exchange) plans sold in South Dakota through healthcare.gov are not required to cover ED medications as an essential health benefit. A minority of Silver and Gold plans include them as supplemental benefits.

For patients whose plan does cover alprostadil, the in-network cost-sharing after meeting the deductible is typically a Tier 3 or Tier 4 copay ranging from $50 to $150 per fill, depending on plan design. FDA drug approval data confirms that both Caverject Impulse (alprostadil alfadex) and MUSE (alprostadil urethral suppository) are approved branded products, and most formularies list them separately, so a patient denied coverage for one formulation should ask the prescriber to request authorization for the other.

Is Compounded Alprostadil Legal in South Dakota?

Yes. South Dakota permits 503A compounding pharmacies to prepare alprostadil for individual patients under a valid prescription. This is consistent with federal law under 21 U.S.C. § 353a, which authorizes state-licensed pharmacies to compound drugs for specific patients when a prescriber writes an individualized prescription.

Compounded alprostadil is commonly prepared as a single-agent injection at concentrations such as 10 mcg/mL, 20 mcg/mL, or 40 mcg/mL, or as part of a combination known as trimix (alprostadil + papaverine + phentolamine) or bimix (alprostadil + papaverine). Combination formulas are not FDA-approved as finished drug products, which is precisely why compounding is the legal pathway for obtaining them. The FDA's guidance on 503A pharmacy compounding makes clear that patient-specific prescriptions routed through a licensed 503A pharmacy are lawful under federal law, provided the bulk substances meet USP standards.

The cost advantage is substantial. Compounded alprostadil from South Dakota-accessible 503A pharmacies (including pharmacies licensed in neighboring states that ship to SD) can cost significantly less than the $600/month brand benchmark, depending on the formula and dose. Trimix formulations in particular offer a dramatic cost reduction because they rely on three low-cost active ingredients rather than alprostadil alone. Some patients pay under $100 per month for compounded trimix.

South Dakota's Board of Pharmacy regulates in-state 503A compounders. Patients should confirm that any online pharmacy shipping compounded alprostadil to a South Dakota address holds a valid non-resident pharmacy license from the South Dakota Board of Pharmacy, verifiable at pharmacy.sd.gov.

The table below summarizes the cost and access framework a prescriber or patient should work through before settling on a specific alprostadil strategy in South Dakota:

South Dakota Alprostadil Cost-Access Decision Framework

1. Check commercial insurance formulary first. If covered with PA, pursue PA with documented PDE5 failure and organic ED etiology.
2. If uninsured or Medicaid-only, skip brand and go directly to 503A compounded alprostadil or trimix.
3. If commercially insured but denied coverage, apply for the Pfizer Caverject savings card and check GoodRx pricing at Sioux Falls or Rapid City pharmacies.
4. If telehealth-accessible (yes, in SD), obtain the prescription remotely; no in-person urology visit is legally required to prescribe alprostadil in South Dakota.
5. Dose-titrate in a clinical setting for intracavernosal alprostadil (Caverject) per the AUA ED guideline before self-injection at home.

Can South Dakota Patients Get Alprostadil via Telehealth?

Yes. Telehealth prescribing of alprostadil is permitted in South Dakota. State law does not prohibit the issuance of a controlled-substance-exempt prescription (alprostadil is not a controlled substance under the DEA schedule) via a synchronous telehealth visit. A prescriber licensed in South Dakota, or a prescriber in another state with a valid South Dakota telemedicine registration, may evaluate a patient via video and issue an alprostadil prescription.

The DEA's telemedicine rules for non-controlled substances do not impose the same prescribing barriers that exist for Schedule III-V drugs, so alprostadil can be prescribed through telehealth without a prior in-person visit in most clinical scenarios. Some telehealth platforms serving South Dakota, including HealthRX, offer virtual evaluation and, where appropriate, a prescription that can be routed to a local retail pharmacy or a licensed 503A compounding pharmacy.

One clinical caution: the Caverject prescribing label and the AUA ED guideline recommend that the first intracavernosal injection occur in a monitored clinical setting to titrate the dose and manage the rare risk of prolonged erection (priapism). Telehealth is appropriate for initial evaluation and prescription issuance, but first-dose titration should occur with a provider present or with immediate access to emergency care.

A 2022 JAMA study of telehealth expansion for sexual health services found that synchronous video visits produced equivalent patient satisfaction and treatment initiation rates compared with in-person visits for ED management, supporting the clinical validity of the telehealth pathway for South Dakota patients.

Discount Programs and Savings Cards for Alprostadil in South Dakota

Several cost-reduction options exist for South Dakota patients paying cash or facing high cost-sharing.

Pfizer Caverject Savings Card. Pfizer has historically offered a savings card for commercially insured patients that reduces the out-of-pocket cost at the pharmacy. The card is typically not valid for Medicaid or Medicare beneficiaries. Eligibility terms change annually, so patients should check Pfizer's savings program page directly before assuming availability.

GoodRx and Similar Discount Aggregators. GoodRx, RxSaver, and NeedyMeds compare pharmacy pricing and offer discount coupons. In South Dakota, GoodRx pricing for generic alprostadil injection at major chain pharmacies (Walgreens, Walmart, CVS) may reduce the cash price by 10 to 30% depending on supply contracts at individual locations. GoodRx coupons cannot be combined with insurance. NeedyMeds maintains a database of patient assistance programs for patients who cannot afford brand-name alprostadil.

Manufacturer Patient Assistance Programs (PAP). Pfizer's RxPathways program offers free or reduced-cost medication for uninsured or underinsured patients meeting income eligibility criteria. Pfizer RxPathways can be accessed at pfizerrxpathways.com, and South Dakota patients without insurance who meet income thresholds below 400% of the federal poverty level may qualify.

Compounded Trimix as a Cost Strategy. As noted above, trimix from a licensed 503A pharmacy is the most cost-effective alprostadil-containing option available in South Dakota. A 2019 Urology review of combination intracavernosal therapy confirmed that trimix produces equivalent or superior efficacy to alprostadil monotherapy in many patients with organic ED, making the switch clinically reasonable, not merely a financial compromise.

How Alprostadil Works: Clinical Pharmacology Relevant to Dosing Costs

Understanding the pharmacology helps patients avoid over-spending on doses they do not need. Alprostadil is prostaglandin E1 (PGE1). When injected intracavernosal at doses between 2.5 mcg and 40 mcg, or delivered as a 125 mcg to 1 to 000 mcg urethral suppository (MUSE), it binds prostanoid receptors to relax trabecular smooth muscle and dilate cavernosal arteries.

Dose titration is the primary driver of both safety and cost efficiency. The Caverject prescribing information approved by the FDA states that dose titration should start at 2.5 mcg for neurogenic ED and 5 mcg for vasculogenic or mixed ED, increasing in 5 to 10 mcg increments under supervision until the minimal effective dose is identified. A patient who requires only 10 mcg per injection spends far less per dose than one titrated to 40 mcg.

The original Linet et al. NEJM trial (N=296) used intracavernosal doses across a 5 to 20 mcg range and reported that 94% of injection attempts produced adequate erections. The trial also noted that penile pain occurred in 50% of patients at some point during the study, a side effect that drives some patients toward MUSE or trimix despite potentially higher costs.

A Cochrane review of alprostadil versus PDE5 inhibitors for ED (Cochrane Database Syst Rev, 2022) concluded that alprostadil injection is more effective than intraurethral delivery and that patient preference drives the choice between these forms. Cost is a decisive factor in that preference for South Dakota patients without strong insurance coverage.

MUSE suppositories (125 mcg, 250 mcg, 500 mcg, 1 to 000 mcg strengths) are generally priced similarly to Caverject on a per-month basis, though per-dose cost may be slightly lower at the 125 mcg and 250 mcg strengths. The FDA label for MUSE recommends no more than two urethral administrations per 24 hours and a maximum of seven doses per week, which constrains monthly supply needs and therefore total monthly cost for lower-frequency users.

Special Populations in South Dakota: Post-Prostatectomy and Diabetic ED

Two groups disproportionately use alprostadil in South Dakota: men who have undergone radical prostatectomy for prostate cancer and men with longstanding type 2 diabetes causing autonomic and vascular neuropathy.

Post-prostatectomy patients often cannot achieve adequate erections with PDE5 inhibitors alone because cavernous nerve injury reduces the nitric oxide signal that PDE5 inhibitors depend upon. Alprostadil bypasses this pathway entirely. A prospective trial published in the Journal of Urology (Montorsi et al., N=30) found that early penile rehabilitation with alprostadil after nerve-sparing prostatectomy increased the rate of spontaneous erection recovery at 6 months compared with untreated controls. This evidence base makes alprostadil a clinically distinct need, not a lifestyle drug, for this population, which strengthens insurance prior-authorization arguments.

Diabetic men with ED have arterial and neuropathic components that often render oral agents insufficient. The American Diabetes Association Standards of Care 2024 (ADA) acknowledge ED as a microvascular complication of diabetes and recommend structured treatment including second-line injectable therapies when first-line agents fail. South Dakota has a relatively high prevalence of type 2 diabetes, at approximately 10.4% of adults according to CDC Diabetes Surveillance data, meaning a sizable share of the state's population may have medical justification for alprostadil coverage appeals.

Practical Steps to Reduce Your Out-of-Pocket Cost in South Dakota

The sequence below reflects the cost-minimization logic most applicable to South Dakota patients in 2026.

First, determine your insurance status and the specific formulary tier for alprostadil at your plan. Call the member services number on your insurance card and ask specifically about NDC codes for Caverject Impulse (alprostadil alfadex for injection) and MUSE (alprostadil urethral suppository). Plans sometimes cover one and not the other.

Second, if coverage is available with prior authorization, ask your prescriber to document organic etiology (diabetes, post-prostatectomy, hypogonadism-related vascular disease) and prior PDE5 inhibitor trial. The AUA ED guideline provides the clinical vocabulary insurers expect to see in a PA request.

Third, if you are uninsured or Medicaid-only, contact a licensed 503A compounding pharmacy that ships to South Dakota and request pricing for compounded alprostadil injection or trimix. Confirm the pharmacy holds a valid South Dakota non-resident license before paying.

Fourth, for brand purchases, apply the Pfizer Caverject savings card or a GoodRx coupon at the time of dispensing. Pfizer's patient savings portal is the authoritative source for current terms.

Fifth, use telehealth if geographic distance from a urology practice is a barrier. South Dakota has significant rural geography; more than 40% of the state's counties are classified as frontier or rural by the U.S. Health Resources and Services Administration. Telehealth closes that distance for evaluation and prescribing, even if first-dose titration still requires a clinical visit.

The standard starting intracavernosal dose of 2.5 mcg should be administered in a clinical setting, with the patient observed for 60 minutes before discharge per the Caverject FDA label. Priapism (erection lasting more than four hours) requires emergency intervention; any South Dakota patient using alprostadil at home should have a clear written plan for what to do if this occurs.